What is the recommended evaluation and treatment for esophageal dysmotility in a patient with multiple sclerosis?

Esophageal Dysmotility in Multiple Sclerosis: Evaluation and Management

Initial Diagnostic Evaluation

Patients with multiple sclerosis presenting with dysphagia should undergo videofluoroscopic swallowing study (modified barium swallow) as the primary diagnostic test to assess both oropharyngeal and esophageal phases of swallowing, as this can detect abnormalities even in asymptomatic MS patients. 1

Key Diagnostic Steps

• Perform videofluoroscopy with multiple bolus consistencies (liquid, semisolid, solid) to evaluate oral preparation, pharyngeal transport, laryngeal penetration, aspiration risk, and upper esophageal sphincter function, as MS dysphagia typically affects oral and pharyngeal phases with delayed bolus transport and decreased pharyngeal contraction. 1, 2

• Screen for silent aspiration, which occurs in approximately 40% of MS patients with dysphagia and represents a critical safety concern that patients cannot self-report. 2

• Obtain upper endoscopy with biopsies at distal, mid, and proximal esophagus to exclude eosinophilic esophagitis and structural lesions that can mimic dysmotility before attributing symptoms solely to MS. 3

• Consider high-resolution esophageal manometry if symptoms suggest true esophageal body dysmotility (chest pain, regurgitation, solid food dysphagia), as recent cohort data show MS patients have 2.09-fold increased odds of achalasia and 3.15-fold increased odds of diffuse esophageal spasm compared to controls. 4

Important Diagnostic Pitfalls

• Do not rely on patient-reported symptoms alone—over 80% of MS patients with advanced disease (EDSS ≥7) have objective swallowing abnormalities on videofluoroscopy, but many are unaware of their aspiration risk. 2

• Recognize that MS dysphagia correlates with severe brainstem impairment (OR 3.24), disease severity (OR 2.99), and cerebellar dysfunction, but not with disease duration. 1

Therapeutic Management Algorithm

Step 1: Dietary and Compensatory Strategies (First-Line for All Patients)

Modify food texture and liquid consistency based on videofluoroscopic findings to ensure safe swallowing—use thickened liquids for patients with delayed swallowing reflex and semisolid foods with high water content to reduce aspiration risk. 1

• Implement chin-tuck (chin-down) posture during swallowing to protect the airway, as this postural maneuver has been specifically validated in MS patients with dysphagia using videofluoromanometry. 1

• Advise patients to fractionate meals into smaller, more frequent portions to reduce muscular fatigue, which is a prominent feature of MS-related dysphagia. 1

• Enrich meals with high-calorie foods and add oral nutritional supplementation if weight loss progresses despite dietary modifications. 1

Step 2: Rehabilitation and Neuromodulation

Refer patients with moderate dysphagia to speech-language pathology for swallowing therapy, including triggering of reflexes and training of the swallowing process, which can improve swallowing function and reduce aspiration risk in neurogenic dysphagia. 1

• Consider pharyngeal electrical stimulation (PES) as an adjunct to conventional swallowing therapy, as electrical stimulation has shown the largest effect sizes among published treatments for MS dysphagia, though evidence remains limited to case series. 5, 6

• Evaluate for repetitive transcranial magnetic stimulation (rTMS) or transcranial direct current stimulation (tDCS) in research settings, though these neuromodulation approaches have minimal published data specifically for MS dysphagia. 6

• Avoid botulinum toxin injection unless there is documented cricopharyngeal spasm on manometry, as evidence for this intervention in MS is limited to small case series. 5

Step 3: Management of True Esophageal Body Dysmotility

If high-resolution manometry confirms achalasia or diffuse esophageal spasm in an MS patient, initiate proton pump inhibitor therapy (omeprazole 20–40 mg twice daily) as first-line treatment, particularly when gastroesophageal reflux symptoms coexist. 3

• Add low-dose tricyclic antidepressant (amitriptyline 10–25 mg at bedtime, titrated to 50 mg) for chest pain or esophageal hypersensitivity associated with spastic disorders. 3

• Use baclofen (5–20 mg three times daily) for predominant regurgitation or belching, with monitoring for CNS side effects that may overlap with MS symptoms. 3

• Refer for pneumatic dilation or per-oral endoscopic myotomy (POEM) only if pharmacologic therapy fails and manometry confirms type III achalasia or refractory diffuse esophageal spasm, recognizing that these interventions carry a 10–40% rate of post-procedure gastroesophageal reflux requiring indefinite PPI therapy. 1, 3

Step 4: Enteral Nutrition for Advanced Dysphagia

Recommend percutaneous endoscopic gastrostomy (PEG) tube placement when patients cannot maintain adequate oral nutrition despite dietary modifications and compensatory strategies, as PEG is the preferred method of enteral nutrition delivery in chronic neurological disorders. 1

• Initiate PEG discussion early in patients with progressive MS phenotypes and severe disability (EDSS ≥7), as these patients have the highest prevalence of unsafe swallowing. 1, 2

• Continue PPI therapy after PEG placement to prevent reflux-related complications, which remain common even with enteral feeding. 1

Critical Clinical Considerations

• MS patients with esophageal dysmotility have significantly higher rates of dysautonomia comorbidities—in the MS/achalasia cohort, 27% have urinary incontinence, 18% have gastroparesis, and 45% have insomnia, suggesting a more severe disease phenotype with extensive neuronal degradation. 4

• Distinguish oropharyngeal dysphagia (oral/pharyngeal phase) from esophageal body dysmotility, as the former is far more common in MS and requires dietary/postural interventions, while the latter may represent concurrent achalasia or spasm requiring pharmacologic or endoscopic therapy. 1, 7, 4

• Provide patients with contact information for on-call teams and instruct them to report chest pain, breathlessness, or acute worsening, as these may indicate perforation if any dilation procedures are performed. 1

• Recognize that evidence for specific dysphagia treatments in MS remains limited—only electrical stimulation and botulinum toxin have been studied in systematic reviews, and both require further research with well-controlled designs to determine long-term efficacy across different MS subtypes and severity levels. 5